Friday, 17 May 2024 11:14 AM
September 28, 2021 16:07 pm
KATHMANDU, Sept 28: Sanofi and GSK have received approval for their Phase 3 clinical study in Nepal to assess the safety, efficacy and immunogenicity of their adjuvant recombinant-protein COVID-19 vaccine candidate.